NEW YORK (GenomeWeb News) — Systems Medicine, a wholly owned subsidiary of Cell Therapeutics, has penned a Cooperative Research and Development Agreement with the National Cancer Institute to develop targeted cancer drugs, Cell Therapeutics said today.

 

Specifically, the five-year alliance calls for the companies to research human monoclonal antibodies, peptides, and small molecules that affect signal transduction through the insulin-like growth factor receptor type I and the insulin receptor.